课题基金 / 基金详情

Novel Vitamin B6 based prodrugs of gemcitabine

Novel Vitamin B6 based prodrugs of gemcitabine
基于吉西他滨的新型维生素 B6 前药
批准号:
8454279
负责人:
Shawn Patrick Zinnen
金额:
$24.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2015-05-31

项目摘要

项目成果

Shawn Patrick Zinnen的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer cells and additional paths to rapid activation once inside cells. Gemcytabine requires activation within a cell before it can demonstrate its anti-cancer activity. The novel compounds will incorporate a form of gemcytabine already preactivated. The specific aims of this project are: (1) To synthesize 5 novel gemcytabine based compounds and assess their stability in plasma and laboratory conditions; and (2), complete characterization of these novel compound's activities in a number of cancer cell lines. This will include quantitation of the compounds effects on cell killing, colony formation ability and cell migration ability. In addition we will quantitate the rate of formation of the most active forms of gemcytabine found within the cells at various times after exposure to the drug and novel compounds. To investigate the mechanism of cellular uptake, activity and bioanalytical endpoints will be assessed in the presence and absence of inhibitors of the standard nucleoside transporters used by Gem. Positive results from this proposed research will provide multiple assets to MBC Pharma's commercialization efforts. A new lead compound for treating pancreatic cancer will provide assets for licensing. In addition, the demonstration of a lead compound from novel drug platform will enable the potential development of multiple compounds for different indications. It is anticipated that this technology will ultimately result in therapeutic agents that will significanty improve the outcomes of cancer patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II
  • 批准号:
    9408695
  • 项目类别:
  • 资助金额:
    $113.85万
  • 财政年份:
    2016
  • 负责人:
    Shawn Patrick Zinnen
  • 依托单位:
Novel Vitamin B6 based prodrugs of gemcitabine
  • 批准号:
    8920750
  • 项目类别:
  • 资助金额:
    $10.1万
  • 财政年份:
    2013
  • 负责人:
    Shawn Patrick Zinnen
  • 依托单位:
NOVEL SELECTION FOR AN AMINO ACTIVATING RNA CATA
  • 批准号:
    2020876
  • 项目类别:
  • 资助金额:
    $2.86万
  • 财政年份:
    1997
  • 负责人:
    Shawn Patrick Zinnen
  • 依托单位:
NOVEL SELECTION FOR AN AMINO ACTIVATING RNA CATA
  • 批准号:
    2172844
  • 项目类别:
  • 资助金额:
    $2.37万
  • 财政年份:
    1996
  • 负责人:
    Shawn Patrick Zinnen
  • 依托单位:
海外基金